Literature DB >> 9712059

Antitumor effect of CD40 ligand: elicitation of local and systemic antitumor responses by IL-12 and B7.

A Nakajima1, T Kodama, S Morimoto, M Azuma, K Takeda, H Oshima, S Yoshino, H Yagita, K Okumura.   

Abstract

The interaction between CD40 ligand (CD40L, CD154) and its receptor CD40 has been implicated in the establishment of cell-mediated immunity as well as humoral immune responses. To examine the role of CD40L in eliciting antitumor immunity, we introduced murine CD40L gene into P815 mastocytoma (CD40L-P815). CD40L-P815 cells underwent prompt rejection when inoculated s.c. into syngenic DBA/2 mice or athymic BALB/c nu/nu mice, which was mediated by NK cells and dependent on endogenous IL-12. The primary rejection of CD40L-P815 cells in DBA/2 mice elicited CD8+ T cell-mediated protective and systemic immunity against parental tumor cells, which was induced by CD4+ T cells and endogenous B7. These results indicated a potent antitumor effect of CD40L that is mediated by potentiation of host Ag-presenting cell functions, and introduction of CD40L will be useful as a new strategy of immuno-gene therapy against tumors.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9712059

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  16 in total

Review 1.  Immunomodulation by thalidomide and thalidomide analogues.

Authors:  L G Corral; G Kaplan
Journal:  Ann Rheum Dis       Date:  1999-11       Impact factor: 19.103

2.  Dendritic cells infiltrating tumors cotransduced with granulocyte/macrophage colony-stimulating factor (GM-CSF) and CD40 ligand genes take up and present endogenous tumor-associated antigens, and prime naive mice for a cytotoxic T lymphocyte response.

Authors:  C Chiodoni; P Paglia; A Stoppacciaro; M Rodolfo; M Parenza; M P Colombo
Journal:  J Exp Med       Date:  1999-07-05       Impact factor: 14.307

Review 3.  Design of CD40 agonists and their use in growing B cells for cancer immunotherapy.

Authors:  Richard S Kornbluth; Mariusz Stempniak; Geoffrey W Stone
Journal:  Int Rev Immunol       Date:  2012-08       Impact factor: 5.311

Review 4.  T-cell-independent antitumor effects of CD40 ligation.

Authors:  Alexander L Rakhmilevich; Kory L Alderson; Paul M Sondel
Journal:  Int Rev Immunol       Date:  2012-08       Impact factor: 5.311

5.  Individual and combined effect of granulocyte-macrophage colony-stimulating factor and prolactin on maturation of dendritic cells from blood monocytes under serum-free conditions.

Authors:  L Matera; A Galetto; M Geuna; K Vekemans; E Ricotti; M Contarini; F Moro; G Basso
Journal:  Immunology       Date:  2000-05       Impact factor: 7.397

6.  Enhancement of effector CD8+ T-cell function by tumour-associated B7-H3 and modulation of its counter-receptor triggering receptor expressed on myeloid cell-like transcript 2 at tumour sites.

Authors:  Hiroko Kobori; Masaaki Hashiguchi; Jinhua Piao; Moriyuki Kato; Patcharee Ritprajak; Miyuki Azuma
Journal:  Immunology       Date:  2010-02-05       Impact factor: 7.397

7.  CD40 ligation prevents Trypanosoma cruzi infection through interleukin-12 upregulation.

Authors:  D Chaussabel; F Jacobs; J de Jonge; M de Veerman; Y Carlier; K Thielemans; M Goldman; B Vray
Journal:  Infect Immun       Date:  1999-04       Impact factor: 3.441

8.  PD-1 preferentially inhibits the activation of low-affinity T cells.

Authors:  Kenji Shimizu; Daisuke Sugiura; Il-Mi Okazaki; Takumi Maruhashi; Tatsuya Takemoto; Taku Okazaki
Journal:  Proc Natl Acad Sci U S A       Date:  2021-08-31       Impact factor: 11.205

9.  Differential graft-versus-leukaemia effect by CD28 and CD40 co-stimulatory blockade after graft-versus-host disease prophylaxis.

Authors:  J Ohata; J Sakurai; K Saito; K Tani; S Asano; M Azuma
Journal:  Clin Exp Immunol       Date:  2002-07       Impact factor: 4.330

Review 10.  CD154 transcriptional regulation in primary human CD4 T cells.

Authors:  Randy Q Cron
Journal:  Immunol Res       Date:  2003       Impact factor: 2.829

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.